These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23913405)

  • 1. Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.
    Lee S; Lee HY; Park KW; Kang HJ; Koo BK; Kim HS; Choi DJ; Kim MA; Oh BH
    Am J Cardiovasc Drugs; 2013 Dec; 13(6):413-24. PubMed ID: 23913405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial.
    Kim SH; Sung JH; Shin J; Lee HJ; Lee HS; Cho DK; Lim SW
    Curr Med Res Opin; 2015 Mar; 31(3):449-57. PubMed ID: 25586295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial.
    Suh JW; Seung KB; Gwak CH; Kim KS; Hong SJ; Park TH; Kim SH; Choi YJ; Joo SJ; Tahk SJ; Kim HS
    Clin Ther; 2011 Aug; 33(8):1057-68. PubMed ID: 21816478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in stroke patients: multicenter, randomized, open-label, phase 4, non-inferiority clinical trial.
    Kang K; Lee SJ; Kim HJ; Koh SH; Kim BK
    Curr Med Res Opin; 2016; 32(1):105-12. PubMed ID: 26443196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet Efficacy of Fixed-Dose Aspirin-Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation.
    Lim S; Kim PJ; Baek C; Kim TH; Koh YS; Park HJ; Kim HY; Chang K; Chung WS; Seung KB
    Clin Drug Investig; 2015 Dec; 35(12):833-42. PubMed ID: 26507618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial.
    Oh PC; Ahn T; Kim DW; Hong BK; Kim DS; Kwan J; Choi CU; Yang YM; Bae JH; Jung KT; Choi WG; Jeon DW; Cho DK; Pyun WB; Cha KS; Cha TJ; Chun KJ; Kim YD; Kim BS; Kim DI; Kim TI
    Int J Cardiol; 2016 Jan; 202():331-5. PubMed ID: 26432484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
    Schulz-Schüpke S; Byrne RA; Ten Berg JM; Neumann FJ; Han Y; Adriaenssens T; Tölg R; Seyfarth M; Maeng M; Zrenner B; Jacobshagen C; Mudra H; von Hodenberg E; Wöhrle J; Angiolillo DJ; von Merzljak B; Rifatov N; Kufner S; Morath T; Feuchtenberger A; Ibrahim T; Janssen PW; Valina C; Li Y; Desmet W; Abdel-Wahab M; Tiroch K; Hengstenberg C; Bernlochner I; Fischer M; Schunkert H; Laugwitz KL; Schömig A; Mehilli J; Kastrati A;
    Eur Heart J; 2015 May; 36(20):1252-63. PubMed ID: 25616646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate.
    Seo KW; Tahk SJ; Yang HM; Yoon MH; Shin JH; Choi SY; Lim HS; Hwang GS; Choi BJ; Park JS; Shin JS; Lee YH; Choi YW; Park SJ; Jin XJ
    Clin Ther; 2014 Nov; 36(11):1588-94. PubMed ID: 25218311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.
    Lee CW; Ahn JM; Park DW; Kang SJ; Lee SW; Kim YH; Park SW; Han S; Lee SG; Seong IW; Rha SW; Jeong MH; Lim DS; Yoon JH; Hur SH; Choi YS; Yang JY; Lee NH; Kim HS; Lee BK; Kim KS; Lee SU; Chae JK; Cheong SS; Suh IW; Park HS; Nah DY; Jeon DS; Seung KB; Lee K; Jang JS; Park SJ
    Circulation; 2014 Jan; 129(3):304-12. PubMed ID: 24097439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease.
    Hamilos M; Saloustros I; Skalidis E; Igoumenidis N; Kambouris M; Chlouverakis G; Vougia D; Loggakis I; Vardas PE; Kochiadakis G
    J Thromb Thrombolysis; 2015 Oct; 40(3):288-93. PubMed ID: 25662861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy.
    Nührenberg TG; Stratz C; Leggewie S; Hochholzer W; Valina CM; Gick M; Kirtane AJ; Stone GW; Neumann FJ; Trenk D
    Thromb Haemost; 2015 Nov; 114(5):1020-7. PubMed ID: 26305340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
    Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Desai B; Tello-Montoliu A; Rollini F; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):42-9. PubMed ID: 22431415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
    Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
    J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
    Valgimigli M; Campo G; de Cesare N; Meliga E; Vranckx P; Furgieri A; Angiolillo DJ; Sabatè M; Hamon M; Repetto A; Colangelo S; Brugaletta S; Parrinello G; Percoco G; Ferrari R;
    Circulation; 2009 Jun; 119(25):3215-22. PubMed ID: 19528337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
    Cannon CP; Husted S; Harrington RA; Scirica BM; Emanuelsson H; Peters G; Storey RF;
    J Am Coll Cardiol; 2007 Nov; 50(19):1844-51. PubMed ID: 17980250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.